Lataa...
The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
(1) Background: Fingolimod (Gilenya(®)) was the first oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Since its approval, the treatment landscape has changed enormously. (2) Methods: Data of PANGAEA and PANGAEA 2.0, two German real-world studies, were descriptively an...
Tallennettuna:
| Julkaisussa: | J Pers Med |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8233755/ https://ncbi.nlm.nih.gov/pubmed/34208513 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11060561 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|